Hence, NSCLC cells with de novo deregulated MET signaling may already be present at baseline; however, their clinical significance in intrinsic resistance seems heterogeneous, possibly because of the polyclonality of resistance mechanisms and different levels of MET signaling deregulation or tumor cell addiction to this signaling. The gene discussed is MET; the disease is non-small cell lung carcinoma.